# Disc Medicine Reports Successful Phase 3 Bitopertin Trial Results

- URL: https://stocks.freetheai.org/news/disc-medicine-reports-successful-phase-3-bitopertin-trial-results-481393
- Published: 2026-10-19T11:13:00Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NASDAQ:IRON](https://stocks.freetheai.org/symbols/NASDAQ-IRON)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Disc Medicine, Inc. (IRON) announced positive topline results from its Phase 3 APOLLO clinical trial evaluating bitopertin. The study met all primary and secondary endpoints, demonstrating a 41.4% reduction in whole-blood metal-free protoporphyrin IX (PPIX) compared to placebo. Patients receiving bitopertin gained an average of 12.2 additional hours of monthly pain-free light exposure at six months.

The trial also highlighted broad treatment benefits, including a 71% decrease in phototoxic reactions and improvements in overall patient quality-of-life measures. Bitopertin was generally well-tolerated during the study, with mild to moderate dizziness reported as the most common side effect in half of the participants.

Following these late-stage trial results, Disc Medicine plans to resubmit a New Drug Application to the U.S. Food and Drug Administration by the end of 2026. A regulatory decision from the agency is expected by mid-2027.

## Key points

- Bitopertin met all primary and secondary endpoints in Disc Medicine's Phase 3 APOLLO trial.
- Patients gained an average of 12.2 hours of pain-free light exposure per month at six months.
- Treatment reduced whole-blood metal-free PPIX levels by 41.4% relative to placebo.
- Phototoxic reactions decreased by 71%, with mild to moderate dizziness as the primary side effect.
- Disc Medicine aims to resubmit its NDA to the FDA by late 2026, expecting a decision by mid-2027.

## Questions and answers

### What were the Phase 3 APOLLO trial results for Disc Medicine's bitopertin?

The Phase 3 trial met all primary and secondary endpoints. Bitopertin reduced PPIX levels by 41.4% versus placebo and increased monthly pain-free light time by an average of 12.2 hours at six months.

### What side effects were reported in the bitopertin trial?

Bitopertin was generally well-tolerated. The most common side effect was mild to moderate dizziness, which occurred in 50% of trial participants.

### When does Disc Medicine expect FDA approval for bitopertin?

Disc Medicine plans to resubmit its New Drug Application to the FDA by the end of 2026 and anticipates a regulatory decision by mid-2027.